Carcinosarcoma of the uterus (CSU) is a rare but aggressive uterine tumor with a poor prognosis. The overall 5-year survival is 43% for all stages. Retrospective studies suggest a correlation between survival and the extent of surgery. This is why surgery includes para and pelvine lymph node dissection. Clear evidence to establish consensus guidelines for treatment – let alone evidence based guidelines – is lacking, however, because CSU are often excluded from major clinical studies on the effects of treatment, including surgery, chemotherapy. The Carcinosarcoma (CUS) study is a prospective registration study of all patients treated for CSU in the of South-West Netherlands region according to the new regional guideline. We aim to disclose risk factors, treatment characteristics and quality-of-life (QoL) aspects. We will compare our data with data from other hospitals in the Netherlands (with different treatment protocols) regarding progression-free and overall survival as well as QoL.
The analysis of treatment variables in relation to progression-free survival (primary endpoint) and overall survival, toxicity and QoL (secondary endpoints) will lead to the consideration of a national randomized controlled trial (RCT).